Why the study?
Diabetic cardiomyopathy remains a significant health concern, necessitating innovative therapeutic approaches.
Does a polyherbal combination improve cardiac health and modulate inflammatory markers in a rat model of diabetic cardiomyopathy?
Does a polyherbal combination improve cardiac health and modulate inflammatory markers in a rat model of diabetic cardiomyopathy?
A polyherbal combination demonstrated cardioprotective, anti-fibrotic, and anti-inflammatory effects in a rat model of diabetic cardiomyopathy, suggesting potential for novel therapeutic interventions.
Does not support clinical use of polyherbal combinations in DCM; leaves open translation from rat models to human therapy.
BACKGROUND: Diabetic Cardiomyopathy (DCM) remains a significant health concern, necessitating innovative therapeutic approaches. This study explores the potential of a polyherbal combination (PHC) in mitigating DCM and delves into the underlying molecular mechanisms. METHODS: Rat models with induced diabetes and cardiomyopathy were administered the polyherbal combination. Molecular analyses included the assessment of ICAM-1, VCAM-1, and NF- κB expression in cardiac tissue. Histopathological and functional evaluations of cardiac health were performed. RESULTS AND DISCUSSION: The polyherbal-treated group showed a significant reduction in blood glucose levels and improved cardiac function, as indicated by increased ejection fraction and cardiac output. Cardiac injury markers, CK-MB and hs-CRP, were significantly reduced by 66.6% and 50% respectively. Lipid profile improvements included lower total cholesterol and triglycerides by 28.5% and 31.1%, respectively. TGF-┘ levels were markedly reduced, suggesting an anti-fibrotic effect. Additionally, NF-κB, ICAM-1, and VCAM-1 expression were significantly downregulated, confirming the polyherbal formulation's anti-inflammatory potential. These findings highlight its cardioprotective effects, making it a promising therapeutic approach for mitigating diabetic cardiomyopathy. CONCLUSION: The study unveils a promising therapeutic strategy for DCM, characterized by the PHC's ability to modulate ICAM-1, VCAM-1, and NF-κB expression. This molecular insight underscores the potential for innovative interventions in managing DCM and offers hope for improved cardiac health in individuals with diabetes.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: